Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PALO ALTO, Calif., June 13, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced their anticipation of expansion in the China Osteoarthritis and Rheumatoid Arthritis market. A complete analysis of current China patents by an intellectual property law firm has rendered the legal opinion that Cellular Biomedicine Group has complete freedom of IP operation with regards to their patents for autologous and allogeneic adipose-derived stem cell compositions for the treatment of osteoarthritis and rheumatoid arthritis, as well as for various stem cell processing and preservation technologies.
Dr. Wei (William) Cao, President of Cellular Biomedicine Group, commented, “In China there are 72.5 Million people suffering from Knee Osteoarthritis (KOA), and 4.5 Million suffering from Rheumatoid Arthritis (RA). We are very confident to enter the world’s largest KOA and RA market with freedom of operation.”
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit:www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
Contact:
Jeff Ramson
Investor Relations
ProActive Capital Group
+1 646-863-6341
Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566 5064
sarah.kelly@cellbiomedgroup.com
SOURCE Cellular Biomedicine Group, Inc.
Help employers find you! Check out all the jobs and post your resume.
